Sling Therapeutics Launches with $35M Series A Financing to Develop Oral Small Molecule for Thyroid Eye Disease - read this article along with other careers information, tips and advice on BioSpace
/PRNewswire/ Sling Therapeutics, Inc., a biopharmaceutical company focused on late-stage development of an oral small molecule for the treatment of thyroid.
Models using novel biomarkers were the most effective predictors of 10-year risk for atherosclerotic cardiovascular disease in patients with chronic kidney disease, a new study found.